FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
The new normal in US oncology approvals
Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?
Will the tills ring for Iovance?
The group has approval for Amtagvi, but now faces the prospect of a solo launch.
Make or break time for Iovance
Lifileucel heads up the list of upcoming US FDA catalysts.
Christmas holiday round-up
As the biotech markets turned bullish the sector’s ups and downs continued.
Tivdak success could make life even harder for Iovance
Seagen/Genmab’s confirmatory cervical cancer trial is toplined positive, putting up a fresh roadblock for Iovance’s accelerated filing plans.
